Pure Global
NCT05961072

Vibrotactile Stimulation With Saphenus Device

Vibrotactile Stimulation for Improved Gait and Pain After Major Lower Extremity Amputation Using a Non-invasive Vibration Device
Massachusetts General Hospital·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Amputation
Drug/Device/Intervention
Vibrotactile sensory feedback device
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Massachusetts General Hospital
Location
Boston, United States of America
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2023
End date
May 01, 2024
Enrollment
50 participants
Primary outcome

Measure Velocity,Measure Endurance,Measure Physical Function,Measure User Satisfaction of Function,Measure Pain Overall,Measure Pain Interference,Measure Pain Intensity

Summary

To determine the benefit of the vvibrotactile sensory feedback device.

ICD-10 classifications
Amputation of limb(s)Traumatic amputation of both feetTraumatic amputation of upper and lower limbs, any combination [any level]Traumatic amputations involving other combinations of body regionsTraumatic amputation of lower leg
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05961072
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05961072 through Pure Global AI's free database. This phase not specified trial is sponsored by Massachusetts General Hospital and is currently Not yet recruiting. The study focuses on Amputation. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.